Contraception
Volume 77, Issue 4 , Pages 264-269 , April 2008

Trends in prescribing patterns of hormonal contraceptives for adolescents

  • Sarah H. O'Brien

      Affiliations

    • Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA
    • Division of Hematology/Oncology, Nationwide Children’s Hospital/Ohio State University, Columbus, OH 43205, USA
    • Corresponding Author InformationCorresponding author. The Research Institute at Nationwide Children's Hospital, J1415 Columbus, OH 43205, USA. Tel.: +1 614 722 3183; fax: +1 614 722 3544.
    • ,
  • Eloise E. Kaizar

      Affiliations

    • Department of Statistics, Ohio State University, Columbus, OH 43210, USA
    • ,
  • Melanie A. Gold

      Affiliations

    • Division of Adolescent Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Kelly J. Kelleher

      Affiliations

    • Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA

Received 20 October 2007 ,Revised 20 November 2007 ,Accepted 15 December 2007.

References 

  1. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965–1976
  2. Petitti DB. Clinical practice. Combination estrogen–progestin oral contraceptives. N Engl J Med. 2003;349:1443–1450
  3. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582–1588
  4. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593–1596
  5. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593
  6. de Jong-van den Berg L, Tobi H, Bijker B, van den Berg P. Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study. BMJ. 2003;326:254
  7. Martin RM, Hilton SR, Kerry SM. The impact of the October 1995 ‘pill scare’ on oral contraceptive use in the United Kingdom: analysis of a general practice automated database. Fam Pract. 1997;14:279–284
  8. National Center for Health Statistics . Ambulatory Health Care Data. Available at http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htmAccessed June 22, 2007
  9. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159:65–70
  10. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187–196
  11. Hing E, Gousen S, Shimizu I, Burt C. Guide to using masked design variables to estimate standard errors in public use files of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Inquiry. 2003;40:401–415
  12. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception. 2006;73:23–29
  13. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007;22:317–322
  14. Ortho Evra [full United States prescribing information]. Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc; 2006;[revised September]
  15. Santelli JS, Lindberg LD, Finer LB, Singh S. Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. Am J Public Health. 2007;97:150–156
  16. Tans G, Bouma BN, Buller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med. 2003;3:61–68
  17. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201–210
  18. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131–134
  19. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354:127–128
  20. Parkinson J, Park S, Wolfe SM, Rosendaal F. Petition to the FDA to ban third generation oral contraceptives containing desogestrel due to increased risk of venous thrombosis (Health Research Group Publication #1799). 2007. Available at http://www.citizen.org/publications/.
  21. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril. 2002;77:S27–S31
  22. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109:339–346
  23. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2006;73:223–228
  24. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354
  25. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–88
  26. Wilks JF. Hormonal birth control and pregnancy: a comparative analysis of thromboembolic risk. Ann Pharmacother. 2003;37:912–916

PII: S0010-7824(08)00012-7

doi: 10.1016/j.contraception.2007.12.009

Contraception
Volume 77, Issue 4 , Pages 264-269 , April 2008

Article Tools

* Image Usage & Resolution